MicroRNAs in skin and wound healing

Jaideep Banerjee, Yuk Cheung Chan, and Chandan K. Sen
Department of Surgery, Ohio State University Medical Center, Columbus, Ohio

Submitted 13 August 2010; accepted in final form 19 October 2010

Banerjee J, Chan YC, Sen CK. MicroRNAs in skin and wound healing. Physiol Genomics 43: 543–556, 2011. First published October 19, 2010; doi:10.1152/physiolgenomics.00157.2010.—MicroRNAs (miRNAs) are small endogenous RNA molecules ~22 nt in length. miRNAs are capable of posttranscriptional gene regulation by binding to their target messenger RNAs (mRNAs), leading to mRNA degradation or suppression of translation. miRNAs have recently been shown to play pivotal roles in skin development and are linked to various skin pathologies, cancer, and wound healing. This review focuses on the role of miRNAs in cutaneous biology, the various methods of miRNA modulation, and the therapeutic opportunities in treatment of skin diseases and wound healing.

miRNA therapy; hypoxia

The skin is the largest organ of the body, accounting for ~15% of total body weight in adult humans (60, 70). The skin protects the body against environmental hazards and prevents dehydration. The skin is made up of three distinct layers of tissue: epidermis, dermis, and hypodermis. The development of these three distinct layers as well as the normal physiological functions of the skin are highly orchestrated physiological processes involving numerous factors and a complex gene regulatory network that act in a temporally resolved integrated manner. The human genome consists of ~20,000–25,000 protein coding genes (28, 88). Although it has been generally assumed that most genetic information is transacted by proteins, recent evidence suggests that the majority of the genomes of mammals and other complex organisms is in fact transcribed into noncoding RNAs, many of which are processed into smaller products. Little is known about these noncoding regions of the genome, which were once regarded as evolutionarily conserved “junk” DNA. MicroRNAs (miRNAs) are a major group of these noncoding RNAs and are now known to regulate almost a third of all the coding genes (104). They are small (~22 nt long) endogenously formed repressors of gene expression. miRNAs usually bind to the 3′-untranslated region of the target messenger RNAs (mRNAs) and are capable of inducing posttranscriptional gene regulation by blocking translation, by degrading the target mRNA, or by doing both (5, 35). miRNAs can be classified into distinct families based on similarity in the 5′ seed sequences because target miRNA recognition depends on the 5′ seed sequence of the miRNA (90, 156). miRNA research in the field of dermatology is in its early phase, but the early finds are substantial, pointing toward a vast opportunity for developing effective therapies for treatment of skin diseases and wounds. The public health impact of chronic wounds is staggering. An estimated 1.3–3 million US individuals are believed to have pressure ulcers; and as many as 10–15% of the population with diabetes are at risk of developing diabetic ulcers, while many more have had venous ulcers or wounds that result from arterial disease (126). Treating these wounds is estimated to cost about $5–10 billion each year (79). miRNA-based therapeutics therefore provide opportunities for addressing chronic wounds as a major public health concern in the US and globally.

Mechanisms Underlying Biogenesis of MicroRNAs

miRNA biogenesis, for the most part, occurs through the following sequential steps (50). miRNAs are encoded in the human genome as miRNA genes and are then processed to mature miRNAs. RNA polymerase II transcribes several-kilobase-long fragments called primary miRNAs (pri-miRNAs), which are then capped and polyadenylated. The microprocessor complex, which is composed of the RNase III enzyme drosophila and DGCR8, then cleaves the pri-miRNAs into ~70-nt-long premiRNAs (pre-miRNA). The resulting premiRNAs are then exported to the cytoplasm through the Ran-GTP-dependent nuclear export factor exportin-5. Another RNase III enzyme, dicer, then cleaves the pre-miRNAs into 18- to 24-nt double-stranded RNAs. The resulting RNA-duplex associates with the miRNA-induced silencing complex (RISC), where one of the strands is degraded while the other becomes the mature miRNA. The mature miRNAs interact with target miRNAs via complementarity binding with a particular region known as “seed sequence.” The resultant complex hinders assembly of ribosome, subsequently suppressing gene expression. An overview of the key processes involved in the biogenesis of miRNA is illustrated in Fig. 1.

At present, a number of databases and online bioinformatics resources are available for miRNA target prediction in silico. Some of the most popular tools are listed in Fig. 2. On the basis
of such resources, it is predicted that more than one-third of the mammalian mRNAs are potential targets of miRNAs (90).

**MicroRNAs in Skin Morphogenesis**

The skin is made of three distinct layers of tissue (130). The epidermis is populated mostly by keratinocytes along with dendritic cells, melanocytes, and Langerhans and Merkel cells. The dermis consists of collagenous and elastic fibers populated by fibroblasts, macrophages, mast cells, and lymphocytes. The dermis also consists of a glycosaminoglycan-proteoglycan fraction that functions as a supporting matrix or ground substance and makes up its base. It is composed of polysaccharides and protein that are linked to produce macromolecules and have important function in wound repair and tissue remodeling. Finally, the hypodermis is composed of adipocyte lobules. The skin contains hair follicles, which are epidermal outgrowths and have a reservoir of stem cells that may regenerate the epidermis (84, 89, 96, 139). The main functions of the skin include barrier defense, UV protection, thermoregulation, pigmentation, sensation of touch and pain, and regulation of water loss from the epidermis (130).

Dicer, which is the miRNA processing enzyme, is present both in the epidermis as well as in the outer root sheath of the hair follicles (1). Skin miRNAs can be classified into distinct groups based on analogy in the 5′ seed sequence of the miRNA (90, 156). Some of the most abundantly expressed skin miRNAs are listed in Table 1 (162). Among these most abundantly expressed miRNAs in the skin, the miRNA-200 and miRNA-19/20 families are heavily expressed in the epidermis while the miRNA-199 family is abundantly expressed highly in the hair.
Table 1. MicroRNAs most abundantly expressed in skin

| miRNA | miRNA-152; miRNA-143; miRNA-126; miRNA-21; miRNA-27a; miRNA-214; miRNA-16; miRNA-203; miRNA-125b; miRNA-34a; miRNA-205; miRNA-27b; miRNA-30b; miRNA-125a; miRNA-191; miRNA-200 family (miRNA-200a, miRNA-200b, miRNA-200c, miRNA-141, miRNA-429); miRNA-199 family (miRNA-199a, miRNA-199b); miRNA-19/miRNA-20 family (miRNA-19b, miRNA-20, miRNA-17-5p, miRNA-93) |

follies (162). This observation suggests that these miRNA families may have lineage-specific functions.

Recent studies underscore the importance of miRNAs in skin development and epidermal differentiation. Dicer depletion in the epidermis results in failure of production of mature miRNAs. A striking difference in the morphogenesis of hair follicles was observed when dicer was depleted in embryonic skin progenitor cells. Mutant mice carrying floxed dicer gene were crossed to CD-1 transgenic mice expressing Cre recombinase under the control of the human keratin-14 promoter to obtain dicer1fl/fl, K14-Cre (conditional knockout) mice. Follicular epithelium progenitors evaginated toward the surface of the skin into the epidermis instead of normal invagination toward the dermis (122, 162). Loss of epithelial dicer affected both the epithelium and epithelial-mesenchymal signaling (1). In addition, absence of hair follicle stem cell marker expression and failure of dermal papilla and maintenance of the hair follicles were evidenced, resulting in stunted, hypoproliferative, and misoriented hair follicles (1). Hyperproliferation also was noted in the epidermis (1), which probably occurred because of arrest of physiological apoptosis, suggesting that the aging dicer-depleted skin might be susceptible to developing tumors. Dicer depletion also led to loss of expression of key signaling molecules such as sonic hedgehog (Shh) and Notch homolog 1 (Notch1) by postnatal day 7 (1), which may be responsible for the hyperproliferative epidermal phenotype (114) in the dicer-depleted epidermis. Inactivation of Notch1 has been also associated with hair loss followed by cyst formation (149), and thus Notch1 has emerged as a key miRNA-regulated protein in the skin that is silenced in response to dicer depletion, resulting in pathological conditions in the skin. Taken together, these data suggest that miRNAs are responsible for regulation of the genes involved in the development of the skin. Specific miRNAs required for the execution of key processes in skin morphogenesis have been identified.

In addition to its role in miRNA biogenesis, dicer has been implicated in the biogenesis of other small RNAs like endogenous small interfering RNAs (endo-siRNAs) and small nuclear (sn)/small nucleolar (sno) small RNAs. Thus whether the observations from the dicer knockout approach may therefore be studied to suit the significance of miRNAs remains an open question. The role of DGCR8, on the other hand, is wholly dedicated to miRNA biogenesis (163). Phenotypically, no significant differences were observed between knockout of DGCR8 and dicer during embryonic skin development (163), thus establishing the fact that in the skin the primary function of both the proteins is miRNA biogenesis and that miRNAs are essential for skin development.

The specific role of miRNA-203 in skin morphogenesis has been tested. miRNA-203 posttranscriptionally represses p63, which is crucial in initiation of epithelial stratification and maintenance of the proliferative potential of mature keratinocytes in the basal layers (76). p63 is strongly expressed in the innermost basal layer, the home of epithelial cells with high clonogenic and proliferative capacity (127). Mice lacking all p63 isoforms have no epidermis, squamous epithelia, or epithelial appendages (103, 157, 158). Thus p63 plays a key role in the formation of epidermis and other stratified epithelia. Between embryonic days 13.5 and 15.5, the expression of miRNA-203 levels in mouse suprabasal cells increases compared with that in basal cells, leading to silencing of p63 expression and thus stalling the proliferation of the epidermis (76, 164). Although miRNA does not seem to completely silence p63 (87), it contributes as a switch between keratinocyte proliferation and differentiation in the adult epidermis. Recently, the mechanism for the induction of miRNA-203 has been reported. Ca2+, a protein kinase C (PKC) activator, is identified as an important signal in epidermal differentiation. Ca2+ regulates miRNA-203 expression in keratinocytes, and therefore miRNA-203 was expected to play an important role in development of the skin (134, 164). Specific inhibitors of PKC (GF109293X and Ro31–8220) were able to block such induction. Activator protein-1 (AP-1) proteins c-Jun and JunB were also found to be able to drive miRNA-203 expression in keratinocytes, thus suggesting that the upregulation of miRNA-203 is dependent on the activation of the PKC/AP-1 pathway (134) (Fig. 3).

MicroRNA Functions in Regulation of Skin Physiology and Pathology

**MicroRNAs in maintenance of skin function.** A key function of the skin is to serve as a first layer of defense against the outside environment. The epidermis is primarily responsible for this barrier function and also prevents loss of water from the organism. E-cadherin is an intercellular adhesion molecule that is specifically expressed in epithelial tissues and plays an important role in maintaining the epithelial architecture (142, 146). E-cadherin is required for the maintenance of proper localization of key tight junctional proteins, and its absence results in permeable tight junctions compromising epidermal barrier function of the skin (146). miRNA-200 and miRNA-205 are both highly expressed in normal skin and have been shown to specifically target ZEB1 and SIP1 (also known as ZEB2), the transcriptional repressors of E-cadherin (57, 74, 107). Thus miRNA-200 and miRNA-205 are expected to positively regulate E-cadherin and seem to be essential in maintaining epithelial stability. However, it must be noted that these studies were performed in cell lines and transformed cells. Therefore the significance of these results in normal skin biology remains to be elucidated.

Another important function of the skin is pigmentation. Human pigmentation involves production and dispersion of melanin by epidermal melanocytes to neighboring keratinocytes (75). Skin pigments are essential for absorbing the harmful ultraviolet radiations <310 nm and also regulate skin vitamin D production (106). miRNAs also have been reported to play a role in regulating skin pigmentation. miRNA profiling was done to compare expression in the skin of alpacas (domesticated species of South American camelids) with brown versus white coat color. Among the differentially expressed
miRNAs, miRNA-25 repressed microphthalmia-associated transcription factor (MITF) in skin melanocytes, which regulates genes linked to coat color like tyrosinase (tyr) and tyrosinase-related protein 1 (172). Regulation of gene expression linked to skin color therefore has been identified as a novel functional role for miRNA-25. miRNA-434-5p is implicated in skin whitening and lightening by targeting tyr and hyaluronidase (hyal) genes (153a). Tyr plays an essential role in melanin production, and therefore Tyr repression by miRNA-434-5p resulted in significant loss of black color in murine skin as well as hair (153a).

MicroRNAs in skin cancer. Skin cancer is classified into malignant melanoma, squamous cell carcinoma, and basal cell carcinoma (71). It is a common disease in all European-derived populations and has shown rapid increases in incidence in developed countries during the past several decades (10, 63, 108). High rates of incidence are found in Australia/New Zealand, North America, and northern Europe, and rapid increases in incidence and mortality are observed in both sexes in many countries, even where rates were formerly low (108).

Melanoma, a malignant tumor of melanocytes, causes the majority (75%) of skin cancer-related deaths (64, 161). A number of miRNAs have now been found to be associated with melanoma, while knowledge about the involvement of miRNAs in the other forms of skin cancer is still limited. The let-7 family has been implicated in the suppression of melanoma development. let-7a represses β3-integrin, while let-7b represses cyclin D1, D3, and A and cyclin-dependent kinase (Cdk)4, all of which play a role in melanoma development (105, 123). A significant upregulation of miRNA-221 and miRNA-222 has been observed in melanomas (49). This increased expression of the miRNAs activates cell proliferation and melanogenesis pathways by targeting p27Kip1 and c-Kit receptor regulation, respectively (49). Treatment with antagoniRs against miRNA-221 and miRNA-222 limited cell growth, invasion, chemotaxis, foci formation, and tumor progression (49), suggesting that approaches to antagonize miRNA-221 and miRNA-222 may have future therapeutic applications against melanoma. miRNA-196a, a miRNA that is strongly downregulated in melanoma cells, results in elevated levels of its target homeobox B7 (HOXB7) (16). HOXB7 acts as a transcription factor for basic fibroblast growth factor (bFGF), which subsequently results in elevated Ets-1 activity and BMP4 expression (20). The induction of BMP4 in turn acts as an inducer of migration of melanoma cells. miRNA-137 is also highly expressed in melanoma cell lines (8). Elevated expression of miRNA-137 represses MITF, which is known to be a master regulator of melanocyte development, survival, and function (8). Increased expression of miRNA-182 in melanoma stimulates the metastatic potential of melanocytes, whereas miRNA-182 downregulation impedes invasion and triggers apoptosis of these cancer cells (124). miRNA-182 targets MITF and FOXO3 (124), both of which antagonize invasion. miRNA-193b is downregulated in metastatic melanoma tissues (24), which represses cyclin D1 (CCND1) by directly binding to the 3' untranslated region. Compromised expression of miRNA-193b results in increased cell proliferation (24). Several other miRNAs dysregulated in skin cancer have been.

Fig. 3. miRNA-203 acts as a switch between keratinocyte proliferation and differentiation in adult epidermis and thus contributes to skin morphogenesis. TPA, 12-O-tetradecanoylphorbol-13-acetate; PKC, protein kinase C; AP-1, activator protein-1.
MicroRNAs and psoriasis. Psoriasis is the most prevalent immune-mediated chronic inflammatory disease of the skin (34), with an estimated prevalence of ~2% of the US population (4). It is characterized by increase in differentiation and proliferation of keratinocytes and epidermal infiltration of inflammatory cells that leads to the formation of skin plaques (120), which are characterized by erythematous lesions covered with silvery scales (4).

To identify miRNAs associated with psoriasis, all human miRNAs registered in miRBase 8.0 in skin lesions of patients with psoriasis were compared with healthy human skin or to lesions from systemic sclerosis patients (98). miRNA-29a targets type I and type III collagens and has been found to be strongly downregulated in skin biopsy and fibroblast samples from systemic sclerosis patients (98). miRNA-29a acts downstream of most of the profibrotic molecules identified previously such as transforming growth factor (TGF)-β, platelet-derived growth factor (PDGF)-B, and IL-1α (98), and therefore targeting miRNA-29 family members as posttranscriptional regulators could be a potent antifibrotic approach.

The miRNAs involved in the pathogenesis of the skin are summarized in Table 2.

MicroRNA Functions in Cutaneous Tissue Repair: Wound Healing

miRNAs are increasingly becoming important as players in wound healing (126). The repair of damaged human skin is a physiological process involving three overlapping phases (17, 18): the inflammatory phase, which is characterized by hemo

stasis and inflammation; the proliferation phase, which includes epithelialization, angiogenesis, granulation tissue formation, and collagen deposition; and the remodeling phase, in which organized deposition of collagen takes place over months even after the wound has closed. The cutaneous wound healing process involves changes in the expression of specific miRNAs at a specific phase of wound healing, and aberrant regulation of these specific miRNAs plays a key role in the abnormal healing of problem wounds (130).

Role of microRNAs in inflammatory phase and as regulators of angiogenesis. The role of miRNAs in the inflammatory phase of wound healing is poorly understood. The inflammatory response to wounding starts with the passive leakage of neutrophils and other leukocytes through the damaged blood vessels into the wound (128). This is followed by a release of chemokines and cytokines like PDGF, platelet factor IV, TGF-β, and TNF-α by the immune cells in the wound (120). Neutrophils and monocytes are then recruited from nearby vessels. Neutrophils have a healing role and kill invading microorganisms. Extravasated monocytes mature into macrophages and demonstrate phagocytic function. Monocytes may be either proinflammatory or anti-inflammatory and proangiogenic. The second category has been found to predominate in the later stages of wound repair (36).

Phagocytes and demonstrate phagocytic function. Monocytes may be either proinflammatory or anti-inflammatory and proangiogenic. The second category has been found to predominate in the later stages of wound repair (36).
One of the important roles of inflammatory cytokines at the wound site is to regulate angiogenesis (143). Endothelial cell migration and capillary formation represent the main aspects of this phase. Sprouting of capillaries into the wound bed is critical to support regenerating tissue, and therefore impairments in wound angiogenesis may lead to chronic problem wounds (22, 31, 54). The first evidence that indicated the involvement of miRNAs in angiogenesis came from the observations that endothelial cell capillary sprouting, migration, and tubulogenesis were inhibited by knockdown of dicer and drosha (78, 129, 135). Dicer is also required for embryonic angiogenesis during mouse development (160), and the deletion of endothelial miRNAs by inactivation of dicer impairs postnatal angiogenic responses to a variety of stimuli, including exogenous vascular endothelial growth factor (VEGF), tumors, limb ischemia, and wound healing (136).

Current studies on miRNAs are mostly in vitro; however, they may provide important clues for further in vivo studies directly addressing the role of microRNAs in angiogenesis and wound healing.

Table 3 lists the key miRNAs implicated in regulating angiogenesis and predicted to have a role in angiogenesis and wound healing.

**Role of microRNAs in proliferative phase.** An essential aspect of the healing sequence in the proliferative phase is reepithelialization, which includes migration and proliferation of keratinocytes from the wound edge (116). Keratinocyte migration has been reported to be faster upon silencing of SH2-containing phosphoinositide 5-phosphatase 2 (SHIP2) and enhanced AKT signaling (165, 166). miRNA-205 has been found to repress SHIP2, which can interfere with the Akt signaling pathway (165, 166). miRNA-184, however, antagonizes the repression of SHIP2 by miRNA-205, and thus miRNA-184 indirectly represses AKT expression (165, 166). Furthermore, miRNA-205 is also required for downregulation of Rho-ROCK1 activity and thus repression of phospho-cofilin expression (165, 166). Dephosphorylated cofilin is active and severs actin filaments and regulates actin polymerization and depolymerization during migration (37). Furthermore, active cofilin increases cell motility (151). miRNA-205 upregulation enhances cell motility.

miRNA-210 is another miRNA that profoundly influences keratinocyte proliferation and thus wound closure (11, 48). miRNA-210 represents a class of miRNAs called “hypoxamiRs,” which are hypoxia sensitive (11, 48). This is of significance in the context of chronic wounds. Most chronic wounds are ischemic in nature. Ischemia is characterized by lack of perfusion, hypoxia (reduction in oxygen delivery below tissue demand), and insufficient nutrient supply. Chronic ischemic wounds are thus essentially hypoxic (125). Extreme near-anoxic hypoxia, as is commonly observed in these wounds, is not compatible with wound repair (125). Hypoxia sensing is generally mediated by a transcription factor called hypoxia-inducible factor (HIF). HIF binds to a hypoxia-responsive element (HRE) in the target genes. HIF, however, has two forms—HIF-1α (and its paralogs HIF-2α and HIF-3α) and HIF-1β. In normoxic conditions, molecular O2 targets HIF for degradation by posttranslational hydroxylation at specific prolyl residues (PHD domains) within these subunits, which increases the affinity for the ubiquitin ligases for proteolytic destruction by the ubiquitin/proteasome pathway. The O2-dependent hydroxylation process is, however, suppressed during hypoxia, resulting in stabilization of HIF-1α and subsequent binding to its constitutive partner HIF-1β to induce
transactivation (125). Stabilization of HIF has been classically known to induce the transcription of coding genes like VEGF, erythropoietin, nitric oxide synthase-2, transferrin, and others (69). The transcriptional regulation of hypoxia-sensitive miRNAs by HIF has been recently reported (21, 81), and among these the most prominent is miRNA-210 (30, 81). miRNA-210 has been reported to be upregulated in hypoxia in almost all cell and tissue types tested (19, 30, 46, 56, 58, 61, 81, 110, 115, 171) and is hypoxia specific, since growth factor deprivation, osmotic stress, acidosis, and oxidative stress do not result in its induction (46).

Among the targets of miRNA-210, transcription factor E2F3, which is necessary for keratinocyte proliferation, has been implicated in wound healing (Fig. 4) (11). A number of E2F3-responsive genes like B-myb, cyclin A, cdc2, cdc6, and DHFR determine the timing of the G1/S transition, the rate of DNA synthesis, and thereby the rate of cellular proliferation (62). Because keratinocyte proliferation is an integral part of wound healing, induction of miRNA-210 and repression of E2F3 hinder closure of ischemic wounds (11).

In another study, the iron sulfur cluster assembly proteins ISCU1 and ISCU2 have been identified as HIF-dependent genes and have been verified to be directly under the control of miRNA-210 (21). ISCU1/2 are essential for iron sulfur cluster biogenesis and are incorporated into wide variety of proteins, many of which, like Complex I and aconitase, are involved in mitochondrial metabolism. Chronic repression of mitochondrial function during hypoxia has been linked to various pathological consequences including ischemic diseases (12, 40, 109, 131). Therefore, this may be another possible mechanism for the observed impairment of closure upon HIF-dependent upregulation of miRNA-210.

MicroRNAs in remodeling: scarred and scarless healing. Collagen deposition is an important aspect of the remodeling phase. As mentioned above, miRNA-29a directly regulates collagen expression at the posttranscriptional level (98). In normal skin fibroblasts, miRNA-29a is under the control of TGF-β, PDGF-B, and IL-4 (98). Mammalian fetal skin can heal without a scar (6, 7, 32, 59), whereas during the late gestational stage it transitions to a scarring phenotype (7, 29). Several miRNAs are differentially expressed between the two stages and probably contribute to this transition (26), and miRNA-29b, miRNA-29c, and miRNA-192 have been found to be the key mediators (26), with their levels being highly induced during the late gestation phase. miRNA-29b and miRNA-29c repress several ECM proteins, antifibrotic TGF-β, and proteins like Smads and β-catenin, which are involved in the signaling pathways important for scarless healing (91, 148).

### Table 3. MicroRNAs involved in different phases of wound healing

<table>
<thead>
<tr>
<th>MicroRNAs</th>
<th>Targets</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inflammatory phase</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-105</td>
<td>TLR2</td>
<td>9</td>
</tr>
<tr>
<td>miR-140</td>
<td>PDGF receptor</td>
<td>42</td>
</tr>
<tr>
<td>miR-146a, miR-125b</td>
<td>TNF-α</td>
<td>132</td>
</tr>
<tr>
<td><strong>Angiogenesis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-17-92</td>
<td>TSP-1, CTGF</td>
<td>38, 135</td>
</tr>
<tr>
<td>miR-126</td>
<td>Sprce1, PIK3R2</td>
<td>51, 80, 150</td>
</tr>
<tr>
<td>miR-130a</td>
<td>GAX, HOXA5</td>
<td>25</td>
</tr>
<tr>
<td>miR-210</td>
<td>EFNA3</td>
<td>46, 115</td>
</tr>
<tr>
<td>miR-296</td>
<td>HGS</td>
<td>154</td>
</tr>
<tr>
<td>miR-378</td>
<td>Fuz-1, Sufu</td>
<td>85</td>
</tr>
<tr>
<td><strong>Proangiogenic miRNAs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-92a</td>
<td>Integrin-α5</td>
<td>13</td>
</tr>
<tr>
<td>miR-17</td>
<td>Janus Kinase 1</td>
<td>39</td>
</tr>
<tr>
<td>miR-15b,miR-16, miR-20a, VEGF</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>miR-20b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-320</td>
<td>IGF-1</td>
<td>152</td>
</tr>
<tr>
<td>miR-221, miR-222</td>
<td>c-kit</td>
<td>112</td>
</tr>
<tr>
<td><strong>Proliferative phase</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-184</td>
<td>Akt</td>
<td>51, 150, 166</td>
</tr>
<tr>
<td>miR-205</td>
<td>SHIP2, Rho-ROCK1</td>
<td>166</td>
</tr>
<tr>
<td>miR-210</td>
<td>E2F3, ISCU 1/2</td>
<td>11</td>
</tr>
<tr>
<td><strong>Remodeling phase</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-29a</td>
<td>Type I and type II collagen</td>
<td>98</td>
</tr>
<tr>
<td>miR-29b,29c</td>
<td>Smads, β-catenin</td>
<td>91, 148</td>
</tr>
<tr>
<td>miR-192</td>
<td>SIP1</td>
<td>72</td>
</tr>
</tbody>
</table>

Fig. 4. Role of miRNA-210 in the impairment of healing in chronic ischemic wounds. HIF, hypoxia-inducible factor.
miRNA-192 enhances collagen 1α2 expression by targeting Smad-interacting protein 1 (SIP1) (72).

**Clinical Applications of MicroRNAs and Therapeutic Strategies in Wound Healing**

miRNA-based therapeutics provides a unique advantage, because by modulating a single miRNA a group of functionally related genes in a pathway can be targeted compared with modulating a single gene at a time as in conventional gene therapy. In addition, miRNAs can be efficiently inhibited both in vitro and in vivo. The levels of aberrantly expressed miRNAs can be reduced while the levels of the beneficial miRNAs are elevated to obtain desired results. The following are some of the clinical and therapeutic applications of miRNAs.

**MicroRNAs as biomarkers.** miRNAs can serve as excellent biomarkers for prognosis of melanoma. In a recent study (86), ~900 miRNA sequences were screened in blood samples of melanoma patients and healthy individuals: 21 statistically significant miRNAs were found to be downregulated and 30 miRNAs were upregulated in blood cells of melanoma patients, compared with blood cells of healthy control subjects. From these, 16 miRNAs were selected based on which the patients were classified as having melanoma or as being healthy. These miRNAs included hsa-miR-186, hsa-let-7d*, hsa-miR-18a*, hsa-miR-145, hsa-miR-99a, hsa-miR-664, hsa-miR-501-5p, hsa-miR-378*, hsa-miR-29c*, hsa-miR-1280, hsa-miR-365, hsa-miR-1249, hsa-miR-328, hsa-miR-422a, hsa-miR-30d, and hsa-miR-17*. This study highlights the outstanding potential of miRNA biomarker profiling from blood cells as a noninvasive biomarker test for melanoma and other forms of cancer. Preliminary reports also indicate that the miRNA biogenesis complex can act as a biomarker for prognosis of chronic ischemic wounds (47).

**Upregulation of potentially beneficial microRNAs.** The overexpression of a miRNA can be achieved with the use of synthetic short double-stranded oligonucleotides (mimics). Mimics are double stranded, with one strand, called guide, whose sequence is same as the mature miRNA while the other, called passenger, is complementary to the mature sequence. Only the guide sequence is incorporated into the RISC complex (47). Another method of miRNA overexpression is the use of lentiviral vectors with built-in miRNA precursor constructs. Initial results from clinical trials using lentivirus have been positive (73, 159); however, further

![Fig. 5. Approaches for miRNA modulation and examples of application. UTR, untranslated region.](http://physiolgenomics.physiology.org/)

**Table: Approaches for microRNA modulation and examples of application.**

<table>
<thead>
<tr>
<th>Types</th>
<th>Target gene</th>
<th>Mechanism</th>
<th>Examples of application</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mimics</strong></td>
<td>Down</td>
<td>Synthetic double stranded oligonucleotides</td>
<td>mir-155 (92-93, 100), mir-15a (14), mir-16 (14)</td>
</tr>
<tr>
<td>Lentiviral Expression vector</td>
<td>Down</td>
<td>Pre-miRNA construct packaged into lentiviral vector</td>
<td>mir-33 (117), mir-34 (65), mir-21 (95)</td>
</tr>
<tr>
<td><strong>Sponge</strong></td>
<td>Up</td>
<td>Reporter gene containing multiple anti-miRNA sequences in its 3' UTR</td>
<td>mir-31 (147)</td>
</tr>
<tr>
<td><strong>Eraser</strong></td>
<td>Up</td>
<td>Reporter gene containing 2 copies of complementary anti-miRNA sequences.</td>
<td>mir-21 (121)</td>
</tr>
<tr>
<td><strong>Mask</strong></td>
<td>Up</td>
<td>Binds to miRNA target sequence on mRNA</td>
<td>miR-1 (155), miR-430 (27)</td>
</tr>
</tbody>
</table>
advancements are required before this technology can be used successfully in humans.

**Downregulation of potentially harmful microRNAs.** As reported for ischemic wounds, miRNA-210 downregulation is expected to be beneficial for healing (11) and this can be achieved by complementary oligonucleotides. Anti-miRNAs essentially act as competitive inhibitors binding to the mature miRNA and also can affect miRNA maturation by binding to the pre-miRNA.

**SPONGES.** Sponges are essentially competitive inhibitors that contain multiple, tandem binding sites to a miRNA of interest. Sponges have a bulge at the position cleaved by the Ago2. They can thus stably interact with the miRNA target that cannot be sliced. Sponges can inhibit miRNA clusters with a complementary heptameric seed. Sponges therefore have the advantage of being able to block all the miRNAs that recognize the same sequence and thus inhibit all the miRNAs of the same family, resulting in a much more effective outcome (47).

**ERASERS.** miRNA “erasers” are similar to sponges, except that they use only two copies of the perfectly complementary antisense sequence of the miRNA (47).

**MASKS.** Since miRNAs regulate hundreds of genes, manipulating miRNA may repress other targets, many of which may be undesirable. To solve this problem, an oligonucleotide is made to bind to the miRNA target sequence of the specific mRNA of interest, thus preventing the miRNA/mRNA association (47). Thus, with this approach, the miRNA interaction with one specific target can be modulated (47). These approaches along with some examples of their application are summarized in Fig. 5.

**In vivo delivery systems.** Successful delivery of the synthetic oligonucleotides listed in Fig. 5 will depend on their resistance to degradation in tissues, specificity, and high binding affinity to the specific miRNA in question. To achieve these goals chemical modifications of the oligonucleotides are often necessary. Delivery of anti-miRNAs to mammalian tissues is generally administered by either of these approaches (47): 1) intravenous injection of antagoniRs (chemically modified cholesterol-conjugated single-strand oligos) or 2) conjugation of RNA oligos with other lipophilic molecules, i.e., high-density lipoproteins. Three forms of chemically modified oligonucleotides that have been used are 1) 2’-O-methyl group (OMe)-modified oligonucleotides; 2) 2’-O-methoxyethyl-modified oligonucleotides, and 3) locked nucleic acid (LNA) (153) (Fig. 6).

Some of the noteworthy successes in the delivery of oligonucleotides to modulate miRNA levels include inhibition of miRNA-21 with a cholesterol-conjugated anti-miRNA in fibroblasts of the failing heart, which decreased interstitial fibrosis and cardiac hypertrophy (140). Exogenous delivery of synthetic let-7b miRNA by intratumoral injection or by intranasal delivery reduced tumor growth in non-small-cell lung cancer (NSCLC) patients, in the k-ras-dependent mouse model of NSCLC (44, 82), and in lung cancer xenograft mouse models (144). let-7b acts as a tumor suppressor, and therefore restoring let-7b level led to negative regulation of its target

### Chemical modifications of oligonucleotides for in-vivo delivery

<table>
<thead>
<tr>
<th>Oligonucleotide Modifications for in-vivo miRNA delivery</th>
<th>Structure</th>
<th>Description/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>2’-O-methyl</td>
<td><img src="image" alt="2’-O-methyl structure" /></td>
<td>Alkylation of the 2’-OH position prevents degradation by ribonucleases.</td>
</tr>
<tr>
<td>2’-O-methoxyethyl</td>
<td><img src="image" alt="2’-O-methoxyethyl structure" /></td>
<td>Higher affinity and specificity to RNA than their O-Me-analogs</td>
</tr>
<tr>
<td>Locked Nucleic Acid</td>
<td><img src="image" alt="Locked Nucleic Acid structure" /></td>
<td>2’-O-modified RNA in which the 2’-O-oxygen is bridged to the 4’-position via a methylene linker to form a rigid bicycle, locked into a C3-endo (RNA) sugar conformation, extremely high affinity.</td>
</tr>
</tbody>
</table>

Fig. 6. Chemical modifications of oligonucleotides for in vivo delivery. OMe, 2’-O-methyl group.
Review

552 microRNAs IN SKIN FUNCTION AND REPAIR

oncogenes such as RAS, MYC, and HMGA2 and cell cycle promoters such as CDCK25A, CDK6, and CCND2, thus reducing tumor growth (67, 68, 99, 119). Systemic delivery of miRNA-26a by adeno-associated virus (AAV) reduced tumor growth in a mouse model of hepatocellular carcinoma (77). Cholesterol-conjugated administration of anti-miRNA-126 suppressed allergic asthma response by airway hyperresponsiveness and inflammation (97). Antagonism of miRNA-122 by systemic administration of a miRNA-122 antisense oligonucleotide reduced plasma cholesterol levels and decreased hepatic fatty acid and cholesterol synthesis rates in mice (43). miRNA-122 is also an essential host factor for hepatitis C virus replication, and inhibition of miRNA-122 in liver cells caused reduction of replicating hepatitis C viral RNAs (83). pre-miRNA-1 cloned into suitable vectors and introduced into mice repressed its target Hand2 (168).

These results heighten interest in miRNA-based therapies.

Clinical Trials of MicroRNA-Mediated Therapy of Skin Diseases

Three clinical trials related to miRNA and skin have been completed but are yet to be reported. The purposes of these studies were (www.clinicaltrials.gov): 1) “MicroRNA Expression and Function in Cutaneous Malignant Melanoma” (completed 2007); 2) “Immunohistochemical Expression Patterns of MicroRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi” (completed 2009); and 3) “Expression Levels of MicroRNA Processing Enzymes Dicer and Drosha in Epithelial Skin Cancer” (completed 2009). A clinical trial study on the “role of miRNA in the development of cutaneous squamous cell carcinoma” is under way and currently recruiting participants.

A phase I clinical trial in which an LNA-based anti-miRNA targeting miRNA-122 was developed as hepatitis C therapy has recently been completed. This further validates the viability of miRNAs as therapeutic targets and miRNA inhibitors and mimics as a new class of drugs (47).

Concluding Remarks

A majority of the human genome is composed of noncoding genes, and as of this date, very little knowledge is available about the functional significance of these noncoding regions. miRNAs are noncoding RNAs that recently have been reported to regulate skin development, pathogenesis of the skin, and wound healing. The discovery of miRNAs has opened up vast therapeutic opportunities. Chronic wounds present a major health burden and drain on resources, and developing newer and more effective treatments has therefore become a necessity. Knowledge of miRNA function in the regulation of wound healing and developing improved miRNA modulation techniques in the skin will help in translating this knowledge into more effective therapies. Of note, the same miRNAs often have been found to have different and contrasting function in different cell types. To solve this problem, a new technology employing laser capture microdissection can be used to perform cell type-specific miRNA studies in vivo and cultured samples.

Recent publications demonstrate the feasibility of using this technique for analysis of genes captured from blood vessels from human tissues (118), prostate cancer epithelial and interstitial stromal cells, and epithelial cells from other regions.

GRANTS

This work was supported by National Institute of General Medical Sciences Grants GM-069589 and GM-077185 to C. K. Sen.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

REFERENCES

19. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J. hsa-miR-210 is induced by
miRNAs IN SKIN FUNCTION AND REPAIR

553

Review


MicroRNAs in Skin Function and Repair


143. Wang YH, Qian RZ, Zhang W, Chen SF, Jin HM, Hu RM. MicroRNA-320 expression in myocardial microvascular endothelial cells...


